20181220-Phase-1-TG4001-EN
Category: 2018
Transgene Announces Financial Calendar for 2019
20181217 Financial calendar 2019 EN
Transgene Announces Upcoming Investor Meetings
20181205-PR-Investors-Meeting-agenda-T1-2019.pdf
Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice
Roland Kratzer, et al. AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website Download the poster here Poster Presentation Collaboration between Transgene – Laboratoire de Recherches Biochirurgicales, Université Paris Descartes, Hôpital Européen Georges Pompidou, Paris, France – Université Paris Diderot, Sorbonne Paris Cité, Paris, France – Hôpital Saint-Louis, Assistance Publique-Hôpitaux… Continue reading Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice
Transgene – Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018
20181112 PR TG0150 Phase 1 data combi AASLD EN
Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study
Claire Fournier, et al. AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website Download the poster here Poster Presentation
myvac™ Viral based vaccine for personalized neoantigen-directed cancer therapy
Christian Ottensmeier, et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation Collaboration between Transgene – University of Southampton, United Kingdom – La Jolla Institute for allergy and immunology, USA – University of Copenhagen, Denmark
Pseudocowpox virus (PCPV), a potent viral vector for both antigen-dependent and independent cancer immunotherapy
Karola Rittner, et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation
Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment
Jean-Baptiste Marchand et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation Collaboration between Transgene – BioInvent International A.B, Sweden
Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference
20181107 SITC Poster EN
